AMGN
Price
$274.70
Change
-$0.01 (-0.00%)
Updated
Sep 18, 12:10 PM (EDT)
Capitalization
147.02B
41 days until earnings call
NVS
Price
$122.14
Change
-$0.33 (-0.27%)
Updated
Sep 18, 01:22 PM (EDT)
Capitalization
235.97B
40 days until earnings call
Interact to see
Advertisement

AMGN vs NVS

Header iconAMGN vs NVS Comparison
Open Charts AMGN vs NVSBanner chart's image
Amgen
Price$274.70
Change-$0.01 (-0.00%)
Volume$102
Capitalization147.02B
Novartis AG
Price$122.14
Change-$0.33 (-0.27%)
Volume$200
Capitalization235.97B
AMGN vs NVS Comparison Chart in %
Loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMGN vs. NVS commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and NVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (AMGN: $274.71 vs. NVS: $122.47)
Brand notoriety: AMGN: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 85% vs. NVS: 84%
Market capitalization -- AMGN: $147.02B vs. NVS: $235.97B
AMGN [@Pharmaceuticals: Major] is valued at $147.02B. NVS’s [@Pharmaceuticals: Major] market capitalization is $235.97B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $685.53B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • AMGN’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, both AMGN and NVS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 3 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).

  • AMGN’s TA Score: 3 bullish, 6 bearish.
  • NVS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NVS is a better buy in the short-term than AMGN.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а -1.36% price change this week, while NVS (@Pharmaceuticals: Major) price change was -3.22% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.12%. For the same industry, the average monthly price growth was -0.28%, and the average quarterly price growth was +11.33%.

Reported Earning Dates

AMGN is expected to report earnings on Oct 29, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.12% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($236B) has a higher market cap than AMGN($147B). AMGN has higher P/E ratio than NVS: AMGN (22.46) vs NVS (17.85). NVS YTD gains are higher at: 30.387 vs. AMGN (8.617). NVS has higher annual earnings (EBITDA): 22.7B vs. AMGN (15.9B). AMGN has more cash in the bank: 8.03B vs. NVS (7B). NVS has less debt than AMGN: NVS (32.6B) vs AMGN (56.2B). NVS has higher revenues than AMGN: NVS (55.2B) vs AMGN (34.9B).
AMGNNVSAMGN / NVS
Capitalization147B236B62%
EBITDA15.9B22.7B70%
Gain YTD8.61730.38728%
P/E Ratio22.4617.85126%
Revenue34.9B55.2B63%
Total Cash8.03B7B115%
Total Debt56.2B32.6B172%
FUNDAMENTALS RATINGS
AMGN vs NVS: Fundamental Ratings
AMGN
NVS
OUTLOOK RATING
1..100
5370
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
4617
SMR RATING
1..100
1429
PRICE GROWTH RATING
1..100
6354
P/E GROWTH RATING
1..100
9779
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMGN's Valuation (14) in the Biotechnology industry is in the same range as NVS (14) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (17) in the Pharmaceuticals Major industry is in the same range as AMGN (46) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.

AMGN's SMR Rating (14) in the Biotechnology industry is in the same range as NVS (29) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.

NVS's Price Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as AMGN (63) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.

NVS's P/E Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as AMGN (97) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNNVS
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
47%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
54%
Bullish Trend 1 day ago
46%
Momentum
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 1 day ago
52%
MACD
ODDS (%)
Bearish Trend 1 day ago
44%
Bearish Trend 1 day ago
41%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 1 day ago
43%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
38%
Advances
ODDS (%)
Bullish Trend 30 days ago
56%
Bullish Trend 14 days ago
49%
Declines
ODDS (%)
Bearish Trend 3 days ago
53%
Bearish Trend 1 day ago
45%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
57%
Aroon
ODDS (%)
Bearish Trend 1 day ago
52%
Bullish Trend 1 day ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HERO34.460.25
+0.73%
Global X Video Games & Esports ETF
DWAS89.750.09
+0.10%
Invesco Dorsey Wright SmallCap Momt ETF
SIFI44.15N/A
N/A
Harbor Scientific Alpha Income ETF
SOXX258.53-0.05
-0.02%
iShares Semiconductor ETF
QMAG22.99-0.04
-0.17%
FT Vest Nasdaq-100 Mod Buffr ETF - Aug

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with ABBV. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then ABBV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
+0.60%
ABBV - AMGN
55%
Loosely correlated
+2.10%
NVS - AMGN
50%
Loosely correlated
-0.25%
GILD - AMGN
49%
Loosely correlated
+1.26%
PFE - AMGN
47%
Loosely correlated
+0.63%
MRK - AMGN
46%
Loosely correlated
+0.06%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.25%
GSK - NVS
67%
Closely correlated
+0.77%
AZN - NVS
61%
Loosely correlated
+0.17%
PFE - NVS
58%
Loosely correlated
+0.63%
JNJ - NVS
55%
Loosely correlated
+0.42%
SNY - NVS
50%
Loosely correlated
+0.27%
More